neurocare CEO Set to Serve a Further 5 Years as Company Marks 10 Years of Innovation and Impact
Leadership continuity positions neurocare for its next decade of global expansion, innovation, and patient impact. MUNICH, DE / ACCESS Newswire...
Year: 2025
Black Book: Global Healthcare Cloud Adoption Surges Toward Enterprise Scale
Black Book's 18-country survey reveals 74% of health systems advancing large-scale rollouts by 2027, fueled by interoperability, AI readiness, and...
Black Book: Global Healthcare Cloud Adoption Surges Toward Enterprise Scale
Black Book's 18-country survey reveals 74% of health systems advancing large-scale rollouts by 2027, fueled by interoperability, AI readiness, and...
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation...
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation...
KIFFIK Biomedical Onboards Industry Leaders Rene Veloso and Dr. Reginald Swift to Expand Business and Clinical Operations
Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operationsRubix Life Sciences...
KIFFIK Biomedical Onboards Industry Leaders Rene Veloso and Dr. Reginald Swift to Expand Business and Clinical Operations
Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operationsRubix Life Sciences...
Infinx Invests in Maverick AI to Bring Real-Time Autonomous Medical Coding to Revenue Cycle Management
Strategic Partnership Combines Maverick's GenAI-Powered Autonomous Agents With Infinx's Deep RCM Expertise to Accelerate Coding Accuracy CUPERTINO, CALIFORNIA / ACCESS...
Infinx Invests in Maverick AI to Bring Real-Time Autonomous Medical Coding to Revenue Cycle Management
Strategic Partnership Combines Maverick's GenAI-Powered Autonomous Agents With Infinx's Deep RCM Expertise to Accelerate Coding Accuracy CUPERTINO, CALIFORNIA / ACCESS...
TridentCare Closes Acquisition of Shoreline Diagnostics, Solidifying Its California Presence With a Market-Leading Clinical Lab
SPARKS, MD / ACCESS Newswire / August 13, 2025 / TridentCare, the leading national provider of portable diagnostic services, has...
TridentCare Closes Acquisition of Shoreline Diagnostics, Solidifying Its California Presence With a Market-Leading Clinical Lab
SPARKS, MD / ACCESS Newswire / August 13, 2025 / TridentCare, the leading national provider of portable diagnostic services, has...
Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain
PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on...
Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain
PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on...
MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy
Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE)...
MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy
Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE)...
Dogwood Therapeutics Reports Second Quarter 2025 Financial Results
- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”)...
Dogwood Therapeutics Reports Second Quarter 2025 Financial Results
- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”)...
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations –...
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations –...
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney...